摘要
目的探讨阿法骨化醇冲击治疗对终末期肾脏病继发性甲状旁腺功能亢进的应用价值。方法选取终末期肾脏病继发性甲状旁腺功能亢进患者50例作为研究对象，所有患者均给予血液透析治疗，并在治疗开始后每日口服0．5μg阿法骨化醇。比较患者治疗前后血磷（P）、血钙（Ca^2＋）、甲状旁腺激素（PTH）指标变化情况及治疗过程中不良反应发生情况。结果治疗后，PTH和P水平明显降低，Ca^2＋水平显著上升，与治疗前比较差异有统计学意义（P〈0．05）；治疗过程中，患者肝功能无变化，无消化道反应，仅2例患者出现高血钙，所有患者均完成整个疗程。结论阿法骨化醇冲击治疗能显著改善终末期肾脏病继发性甲状旁腺功能亢进患者的血钙、血磷以及甲状旁腺激素水平，减轻患者临床症状，且无明显不良反应，安全性较高，值得一临床推广应用。
Objective To study the application value of alfacalcidol pulse therapy in treatment of end-stage renal disease with secondary hyperparathyroidism. Methods Selected 50 patients with sec- ondary hyperparathyroidism of end-stage renal disease as study object. All the patients were treated with hemodialysis treatment, and they were orally took 0. 5μg alfaealcidol after the treatment begins. The changes of blood phosphate （ P）, blood calcium （ Ca^2＋） , parathyroid hormone （ FFH）, and adverse re- actions during treatment were compared between before and after treatment. Results After treatment, the levels of PTH and P significantly decreased, and the level of Ca2 ＋ increased, the difference was statis- tically significant （P 〈 0. 05 ） ; during treatment, the patients had no liver function changes and gastroin- testinal reactions, only two patients had high blood caluium, and all the patients completed the course of treatment. Conclusions Alfacalcidol pulse therapy in treatment of end-stage renal disease with secondary hyperparathyroidism can improve the levels of Ca^2＋ , P and PTH, reduce clinical symptoms, have higher safety and no obvious adverse reactions, which is worthy of clinical promotion and application.
作者
朱明志
李荣华
李拔敏
Zhu Mingzhi, Li Ronghua, Li Bamin(Two District of Nephrology , Gaozhou People＇ s Hospital, Gaozhou 525200, Chin)
出处
《中国实用医刊》
2018年第8期55-57,共3页
Chinese Journal of Practical Medicine
